Compare MINISO Group Holding Ltd (MNSO) vs 10X Genomics Inc (TXG) Price & Performance

MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing estimates in three of the last four quarters but beating in Q1 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 5.35%. Analyst sentiment is mixed with a 60% buy rating, while recent news highlights CFO share purchases and a 52-week low.

The outlook for MNSO hinges on improving earnings consistency and margin stabilization. Investment opportunities include attractive valuation multiples like a P/E of 14.55 and P/S of 0.78, but risks involve volatile earnings, overseas margin pressures, and competitive retail dynamics. The stock's recent decline to near 52-week lows may present a value entry if operational improvements materialize.

10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.

The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.